Skip to main content
Clinical Trials/ACTRN12606000404527
ACTRN12606000404527
Completed
Phase 3

A randomised placebo-controlled trial of testosterone undecanoate in obese men as adjuvant therapy for a weight loss program

The Woolcock Institute of Medical Research0 sites60 target enrollmentSeptember 14, 2006

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Obstructive Sleep Apnea (OSA)
Sponsor
The Woolcock Institute of Medical Research
Enrollment
60
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 14, 2006
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
Male

Investigators

Sponsor
The Woolcock Institute of Medical Research

Eligibility Criteria

Inclusion Criteria

  • No significant uncontrolled medical problems.

Exclusion Criteria

  • Severe OSA ((minimum oxygen saturation \< 65% or RDI \> 80\) requiring immediate treatment due to severity or increased associated risk (eg Transport worker), Use of drugs that alter androgen action, Contraindications to testosterone therapy, Desire for paternity within the next 12 months, Participation in sports that ban testosterone and require drug monitoring, Psychiatric disorders or drug abuse unless well controlled,Chronic medical conditions likely to interfere with or influence study treatment or safety unless well controlled.

Outcomes

Primary Outcomes

Not specified

Similar Trials